PROCTER & GAMBLE HEALTH LTD.
NSE : PGHLBSE : 500126ISIN
CODE : INE199A01012Industry : Pharmaceuticals & DrugsHouse
: Merck - MNC
BSE4749.20-60.95 (-1.27 % )
PREV CLOSE (Rs.) 4810.15
OPEN PRICE (Rs.) 4752.20
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 637
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE4750.60 -63.8 (-1.33 % )
PREV CLOSE(Rs.) 4814.40
OPEN PRICE (Rs.) 4779.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 4750.60 (49 )
VOLUME 32440
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 27-Mar-2024 | Procter & Gamble Hygiene and Health Care informs about disclosure | <div style="text-align: justify;">Procter & Gamble Hygiene and Health Care has informed that the Company has arrived at an advanced pricing agreement with the tax authorities on March 26, 2024, determining appropriate transfer pricing methodology for certain identified transactions with Company's affiliate(s) for the years viz., F.Y. 2010-11 to F.Y. 2018-19. As a consequence of this agreement; 1. An additional tax liability, approximately of about Rs 36 crores (including interest) is payable. 2. There will be a reduction in contingent liabilities of approximately Rs 87 crores, subject to withdrawal of relevant tax litigations by the respective parties.</div><div style="text-align: justify;"><span style="text-align: left;"><br></span></div><div style="text-align: justify;"><span style="text-align: left;">The above information is a part of company's filings submitted to BSE.</span></div> |
| 04-Mar-2024 | Procter & Gamble Health informs about loss of share certificates | <p style="text-align: justify;">Procter & Gamble Health has informed that it has received information from its Registrars and Share Transfer Agents (RTA), KFin Technologies on March 1, 2024 regarding the loss /misplacement of the share certificate(s) as details enclosed. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 06-Feb-2024 | Procter & Gamble Health informs about corporate action | <div>Procter & Gamble Health has informed that the Board has approved interim dividend for Financial Year 2023-24 at its meeting held today. It has enclosed details regarding record date and payout of said dividend.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 20-Jan-2024 | Procter & Gamble Health informs about loss of share certificates | <div style="text-align: justify;">Procter & Gamble Health has informed that it has been informed by its Registrars and Share Transfer Agents (RTA), KFin Technologies has informed regarding the loss /misplacement of the share certificate(s) as details enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 21-Dec-2023 | Procter & Gamble Health informs about loss of share certificate | <div style="text-align: justify;">Procter & Gamble Health has informed that it received intimation from Registrars and Share Transfer Agents (RTA), KFin Technologies regarding the loss /misplacement of the share certificate(s) as enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 18-Dec-2023 | Procter & Gamble Health informs about loss of share certificate | <p style="text-align: justify;">Procter & Gamble Health has informed that its Registrars and Share Transfer Agents (RTA), KFin Technologies has received information on December 16, 2023, regarding the loss /misplacement of the share certificate(s) as details enclosed. </p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 30-Oct-2023 | Procter & Gamble Hygiene & Health Care informs about outcome of board meeting | <div>Procter & Gamble Hygiene & Health Care has informed that at a meeting of the Board of Directors of the Company held today (commenced at 4.25 pm and ended at 4:53 pm), the Unaudited Financial Results for the quarter ended September 30, 2023 were approved. It enclosed the following: Unaudited Financial Results for the quarter ended September 30, 2023; Press Release; and Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2023 furnished by Statutory Auditors of the Company. </div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 21-Oct-2023 | Procter & Gamble Health informs about loss of share certificates | <div style="text-align: justify;">Procter & Gamble Health has informed that its Registrar and Transfer Agent, Kfin Technologies on October 19, 2023 regarding loss/ misplacement of share certificate(s) as detailed in enclosed letter. </div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 27-Sep-2023 | Procter & Gamble Health to discontinue production of injections at Goa plant | <p style="text-align: justify;">Procter & Gamble Health has planned to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023. The Company is outsourcing manufacturing of the injections portfolio with an intent to achieve cost efficiency and supply optimization.</p><p style="text-align: justify;">The injections portfolio, procured from the Company's manufacturing facility at Goa, accounted for revenue of Rs 102.92 crore during the financial year 2022-23, constituting 8.37% of the Company's total revenue. Discontinuation of production at Company's plant in Goa shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer.</p><p style="text-align: justify;">Procter & Gamble Health is one of India's largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.</p><div style="text-align: justify;"><br></div> |
| 27-Sep-2023 | Procter & Gamble Health informs about disclosure | <p style="text-align: justify;">Pursuant to the provisions of Regulation 30 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Procter & Gamble Health has informed that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023. The injections portfolio, procured from the Company's manufacturing facility at Goa, accounted for revenue of Rs 102.92 crores during the financial year 2022-23, constituting 8.37% of the Company's total revenue. Discontinuation of production at Company's plant in Goa, shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer. The Company is outsourcing manufacturing of the injection's portfolio, with an intent to achieve cost efficiency and supply optimization.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
